Rapid and complete reconstitution of autologous haemopoiesis after cord blood infusion in treatment-naive patients with severe aplastic anemia receiving high-dose cyclophosphamide/ATG therapy

European Journal of Haematology

Volumn 90, Issue 1, 2013, Pages 45-50

  Li, Yanxiang ^a   Sheng, Zhixin ^b,c   Niu, Shaona ^d   Ge, Lifu ^e   Ren, Cuiai ^c   Zou, Yandun ^f  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

^c WEIFANG PEOPLE'S HOSPITAL   (China)

^d LINYI PEOPLE'S HOSPITAL   (China)

^e JINAN MILITARY GENERAL HOSPITAL   (China)

^f GUANGDONG WOMEN AND CHILDREN HOSPITAL   (China)

Author keywords

Cord blood; High dose cyclophosphamide; Severe aplastic anemia

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; APLASTIC ANEMIA; ARTICLE; AUTOLOGOUS HEMOPOIESIS; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFUSION; MALE; MEMBRANE RECONSTITUTION; MONONUCLEAR CELL; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; SCHOOL CHILD; SEROLOGY; SERUM SICKNESS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TREATMENT RESPONSE; UMBILICAL CORD BLOOD;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; BLOOD TRANSFUSION, AUTOLOGOUS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; FETAL BLOOD; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871238325     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12033     Document Type: Article

References (24)

1. Storb R, Blume KG, O'Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001;7:39-44.
2. Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EMBT SAA Working Party. Blood 1995;85:1348-53.
3. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, Freund M, Meusers P, Salama A, Heimpel H. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991;324:1297-304.
4. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe aplastic anemia. Blood 1995;85:3058-65.
5. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289:1130-5.
6. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood 2000;95:1931-4.
7. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in acquired severe aplastic anemia following high-dose cyclophosphamide. Blood 1996;87:491-4.
8. Brodsky RA, Sensenbrenner LL, Smith BD, Dorr D, Seaman PJ, Lee SM, Karp JE, Brodsky I, Jones RJ. Durable treatment-free remission following high-dose cyclophosphamide for previously untreated severe aplastic anemia. Ann Intern Med 2001;135:477-83.
9. Brodsky RA, Chen AR, Dorr D, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood 2010;115:2136-41.
10. Jaime-Perez JC, Gonzalez-Llano O, Gomez-Almaguer D. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. Am J Hematol 2001;66:71.
11. Tisdale JF, Dunn DE, Geller N, Plante M, Nunez O, Dunbar CE, Barrett AJ, Walsh TJ, Rosenfeld SJ, Young NS. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 2000;356:1554-9.
12. Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood 2011;117:936-41.
13. Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-16.
14. Francese R, Fiorina P. Immunological and regenerative properties of cord blood stem cells. Clin Immunol 2010;136:309-22.
15. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, Santos G, Gordon-Smith EC, Storb R. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979;53:504-14.
16. Storb R, Blume KG, O'Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001;7:39-44.
17. May WS, Sensenbrenner LL, Burns WH, Ambinder R, Carroll MP, Griffin CA, Jones RJ, Miller CB, Mellits ED, Vogelsang GB. BMT for severe aplastic anemia using cyclosporin. Bone Marrow Transplant 1993;11:459-64.
18. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289:1130-5.
19. Galotto M, Berisso G, Delfino L, et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999;27:1460-6.
20. Kemp K, Morse R, Sanders K, Hows J, Donaldson C. Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells. Ann Hematol 2011;90:777-89.
21. Pereira RF, Halford KW, O'Hara MD, Leeper DB, Sokolov BP, Pollard MD, Bagasra O, Prockop DJ. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 1995;92:4857-61.
22. Sandmaier B, Storb R, Kniley J. Evidence of allogeneic stromal engraftment in bone marrow using canine mesenchymal stem cells. Blood, 1998;92:116a.
23. Devine SM, Bartholomew A, Sher D, Sturgeon C. Studies of mesenchymal stem cells in non-human primates: evaluation of toxicity and engraftment [abstract]. Blood 1999;94(suppl 1):246.
24. Yoshimi A, Kojima S, Taniguchi S, et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant. 2008;14:1057-63.